Details for Patent: 8,663,687

« Back to Dashboard

Summary for Patent: 8,663,687

Title:	Film compositions for delivery of actives
Abstract:	The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain at least one active agent, which may be administered to a user topically, transmucosally, vaginally, ocularly, aurally, nasally, transdermally or orally.
Inventor(s):	Garry L. Myers, Richard C. Fuisz
Assignee:	Aquestive Therapeutics Inc
Application Number:	US12/779,316
Patent Claim Types: see list of patent claims	Use; Composition; Device;

Scope and Patent Landscape for US Patent 8,663,687 (Self-Supporting Film with Uniformly Distributed Saccharide-Polymer System and Small-Scale Topical Particles)

What does US Patent 8,663,687 claim and what is the practical scope of protection?

US 8,663,687 claims topical delivery compositions and manufacturing methods built around (1) a self-supporting film and (2) a uniform distribution of “small-scale particles” (nanoparticles, micelles, microdroplets, microparticles, liquid crystals, and combinations) in a polyethylene oxide plus saccharide-based polymer matrix, with uniformity defined at the level of equally sized unit doses within ±10% by weight.

Core independent claim theme: “self-supporting film + uniformly distributed small-scale topical particles”

Claim 1 is the anchor claim. It requires all of the following, in combination:

1. A self-supporting film composition
2. Polymer composition
   • Water soluble polymer composition comprising polyethylene oxide (PEO) and
   • a saccharide-based polymer
3. Topical agent present as a small-scale particle selected from:
   • nanoparticle, micelle, microdroplet, microparticle, liquid crystal, and combinations
4. Uniform distribution
   • uniformity is measured by equally sized individual unit doses
   • doses do not vary by more than 10% by weight from a desired dose

Claims 2 and 3 narrow the “topical agent” type to:

• Claim 2: liquid crystal
• Claim 3: micelle

Claim 4 adds a functional targeting/attachment limitation:

• topical agent bound to at least one ligand

Dosage-article framing: claim 5 expands to “dosage composition”

Claim 5 recasts the same film system into a dosage composition with:

• a self-supporting film comprising at least one polymer and at least one agent
• agent defined the same way: small-scale particle types and uniformity by ±10% unit-dose variation

This is a typical strategy: capture both product-by-composition and dosage-by-article.

Claims 6 and 7 narrow particle type (liquid crystal; micelle). Claim 8 adds ligand binding.

Manufacturing claims: method protection is broad but anchored to the same “uniformity” outcome

Claim 9 is the main method claim: forming a self-supporting film dosage composition by:

1. Providing a polymeric matrix
2. Forming a small-scale form of the agent (nanoparticle/micelle/microdroplet/microparticle/liquid crystal or combinations)
3. Dispersing the small-scale form throughout the polymeric matrix
4. Drying to form a self-supporting film
5. Uniform distribution is required, measured by equally sized unit doses within ±10% by weight

The remaining method claims add process-specific embodiments and drying kinetics that are likely meant to distinguish prior art.

Process-formation routes expressly claimed

• Claim 12: emulsion processing
• Claim 13: milling
• Claim 14: microfluidics pumping apparatus
• Claim 22: high shear apparatus

These are non-exclusive in the sense that the independent method claim already covers dispersing and drying; the dependent claims add alternative formation techniques for the small-scale agent.

Application route explicitly claimed

• Claim 24 provides a second method track:
  • Provide polymeric matrix
  • Form small-scale form
  • Apply to polymeric matrix via deposition
  • Dry to self-supporting film
  • Keep uniformity at ±10% unit-dose variation

This can matter for infringement, because deposition is a different manufacturing approach than “dispersing throughout.”

Particle and targeting variants

• Claim 10: microdroplet (method)
• Claim 11: micelle (method)
• Claim 15: agent bound to ligand (method)
• Claims 23 and 32: liquid crystal (method)

The “drying kinetics / lock-in” limitation (high-value differentiator)

Claims 16 to 21 introduce a timed drying behavior:

• Claim 16: heating the polymeric matrix so that a visco-elastic mass forms rapidly and maintains uniform distribution by locking-in or preventing migration within the first 10 minutes or less.
• Claim 17: polymeric matrix containing the agent varies no more than 10% by weight throughout the matrix.
• Claim 18: further drying yields a self-supporting film with solvent content ≤10%.
• Claims 19-21: tighter kinetics and solvent constraints:
  • visco-elastic mass formation occurs within 0.5 to about 10 minutes (Claim 19)
  • matrix variation no more than 10% by weight (Claim 20)
  • final solvent content ≤10% (Claim 21)

In claim-scope terms, this set of dependents can be used two ways:

1. To narrow to a manufacturing approach likely to be most defensible against obviousness.
2. To enforce at least some infringement scenarios where a competitor’s process still produces the “locked-in” uniformity.

If a competitor achieves ±10% uniform unit dosing without using the specific “rapid visco-elastic lock-in” window, claims 16-21 may not read, but claim 9 and claim 24 can still be asserted because those don’t require the time-to-visco-elastic formation.

What is the key novelty captured by the claim language (uniform unit-dose ±10% distribution)?

The claims tie IP coverage to a quantified distribution standard that is measured at the level of equally sized unit doses.

How the ±10% uniformity requirement constrains scope

• The distribution must be measured as unit-dose variability by weight, not just a qualitative “uniform dispersion.”
• The tolerance is ±10% from a desired dose.
• The unit-dose sizing must be equally sized individual unit doses, which implies a specific dosing segmentation method (e.g., cut film units or metered film sections).

Why this matters for infringement and design-around

• A competitor could attempt a design-around by manufacturing films that fail the ±10% unit-dose uniformity standard, but that risks product quality and dose reliability.
• Another design-around is to keep the dose uniform while avoiding specific claimed polymer composition elements (PEO + saccharide polymer), because claim 1 explicitly requires both.

Which formulation elements are required vs optional in US 8,663,687?

Required in claim 1 (strongest claim composition scope)

• Self-supporting film
• Water soluble polymer composition comprising:
  • polyethylene oxide
  • saccharide-based polymer
• Topical agent as one of the listed small-scale particle types
• Uniform distribution: equally sized unit doses with ≤10% weight deviation

Optional / dependent additions

• Liquid crystal specifically (claims 2, 6, 23, 32)
• Micelle specifically (claims 3, 7, 11, 26)
• Ligand binding (claims 4, 8, 15, 30)
• Process route selection (claims 12-14, 22; and deposition route via claim 24-32)

What are the likely protective claim “buckets” in the patent estate around this technology?

Based on the claim set (film, PEO+saccharide polymers, small-scale particles, uniformity quantified by unit-dose weight variation, plus manufacturing methods), US 8,663,687 typically clusters with adjacent patent families covering:

1. Film matrix compositions
   • PEO + saccharide polymer combinations
   • water solubility and film-forming performance
2. Topical agent carrier forms
   • nanoparticles vs micelles vs microdroplets vs liquid crystals
   • ligand-functionalized variants
3. Manufacturing processes
   • emulsion, milling, microfluidics, high shear
   • dispersion vs deposition workflows
   • fast drying kinetics / visco-elastic lock-in
   • solvent content ≤10%
4. Dose uniformity metrology and unit-dose handling
   • how “equally sized unit doses” are defined
   • how weight deviation is measured

Without tying to the patent’s full specification and family members, the safest conclusion is that the claims are written to cover both:

• product form (film + particle distribution), and
• process-to-outcome manufacturing.

What patent expiration and exclusivity timing applies to US 8,663,687?

No expiration date, filing date, or priority date is provided in the prompt. Without those, any statement about patent term, PTA, or regulatory exclusivity would be inaccurate.

Is US 8,663,687 listed in the FDA Orange Book for any approved product?

The prompt provides no Orange Book entry, NDA/BLA, applicant, or listed patents. Without that, it is not possible to determine Orange Book status for US 8,663,687.

How broad is infringement risk for a generic or follow-on topical film using small-scale particles?

The practical infringement analysis hinges on whether a competitor’s product matches the independent claim elements:

High-risk overlap scenarios

1. Self-supporting film for topical delivery (common in “film strip” or thin-film formats)
2. Water-soluble polymer film containing PEO + a saccharide-based polymer
3. Active loaded as small-scale particle (nanoparticle/micelle/microdroplet/microparticle/liquid crystal)
4. Dose segmentation yields unit doses with ≤10% weight deviation for the particle-containing agent distribution

If all four align, claim 1 and claim 5 are plausible targets.

Key design-around levers

• Remove one required polymer element:
  • omit saccharide-based polymer or omit PEO (claim 1).
• Change the particulate carrier form outside the enumerated list:
  • the claim lists specific categories; a carrier not fitting nanoparticle/micelle/microdroplet/microparticle/liquid crystal could avoid literal scope, depending on doctrine of equivalents.
• Fail the quantified dose uniformity requirement:
  • if unit-dose variability exceeds 10% by weight, claim 1/5/9/24 may not read.

How do the method claims expand enforcement beyond the finished film?

Even if a competitor argues composition differences, method claims can reach manufacturing workflows:

Dispersion-and-drying route

• Claim 9 covers: forming small-scale agent → dispersing into polymeric matrix → drying to self-supporting film → achieve uniform unit-dose distribution.

Deposition-and-drying route

• Claim 24 covers deposition rather than full dispersion.

If a competitor loads by coating/deposition and still lands within the unit-dose uniformity window, claim 24 becomes an enforcement lever.

Process embodiment dependence vs core method requirement

The formation-process dependents (emulsion, milling, microfluidics, high shear) are additional constraints, not prerequisites for claim 9/24. Core infringement can still be pursued if a competitor forms small-scale particles by any other technique, so long as the method results in the claimed uniformity distribution after drying.

“Lock-in” drying kinetics claims

Claims 16-21 target a specific manufacturing technique:

• heating to produce a visco-elastic mass that prevents migration within 10 minutes (or 0.5 to 10 minutes)
• solvent content ≤10%

Competitors using slower gelation or drying that does not create early visco-elastic lock-in could be argued out of these dependents, but still risk independent method claims if the final product meets the uniformity limitation.

What is the technical scope of “small-scale particles” as claimed?

US 8,663,687 is structured to treat the topical agent as a pre-formed carrier form distributed throughout the film matrix. The enumerated categories function like buckets:

• Nanoparticles
• Micelles
• Microdroplets
• Microparticles
• Liquid crystals
• Combinations

The claims do not require a specific particle size distribution or composition in the excerpt provided. They instead require:

• the existence of the “small-scale particle” type, and
• uniform distribution by unit-dose weight within ±10%.

Which claim limitations are likely to be litigated: polymer identity, uniformity measurement, or carrier category?

Given how the claims are written, the most common infringement disputes are likely to be:

1. Whether the polymer matrix includes both PEO and a saccharide-based polymer (claim 1)
2. Whether the competitor’s agent qualifies as one of the enumerated small-scale categories
3. How unit-dose uniformity is measured
   • equal unit sizing
   • sampling and weight deviation calculations
4. Whether the manufacturing method achieves the claimed outcome uniformity, especially for method claims 9 and 24
5. Whether the competitor uses the specified visco-elastic lock-in and solvent ≤10% for dependents 16-21

Key Takeaways

• US 8,663,687 protects self-supporting topical films made from water-soluble PEO plus saccharide-based polymers with a topical agent carried as uniformly distributed small-scale particles.
• The claims are anchored to a quantifiable distribution standard: equally sized unit doses with ≤10% by weight deviation of the small-scale particle from the desired dose.
• Enforcement can target both finished films (claims 1 and 5) and manufacturing methods (claims 9 and 24), with additional process-specific protection via emulsion/milling/microfluidics/high shear and deposition routes.
• Claims 16-21 add a manufacturing kinetics “lock-in” concept (rapid visco-elastic mass formation within ≤10 minutes and solvent content ≤10%), which can matter for process-based infringement theories.

FAQs

1. Does US 8,663,687 require a specific topical indication (dermatology vs ocular vs systemic)?
   The excerpt frames the agent as “topical” but does not tie to a specific therapeutic indication.

2. Can a film with uniform dosing but using only one of PEO or saccharide polymer avoid claim 1?
   Claim 1 requires both PEO and a saccharide-based polymer in the water soluble polymer composition.

3. Are ligand-functionalized agents covered only in dependent claims?
   Ligand binding is introduced in dependent claims (e.g., claims 4, 8, 15).

4. Does the patent cover both dispersion and deposition manufacturing methods?
   Yes. Claim 9 covers dispersion in a polymeric matrix; claim 24 covers deposition.

5. What is the primary quantitative standard for distribution in the claims?
   Unit-dose weight deviation of the small-scale particle from the desired dose must not vary by more than 10%.

References

1. USPTO, US Patent 8,663,687. Claims excerpt provided in prompt.

Drugs Protected by US Patent 8,663,687

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 8,663,687

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077803
Austria	E536868
Austria	E536869
Austria	E553746
Australia	2002332118